AEON Biopharma Inc. has announced positive scientific research results demonstrating robust biosimilarity between its product ABP-450 (prabotulinumtoxinA) and BOTOX (onabotulinumtoxinA). The company confirmed a 100% match in the visible amino acid sequence and reported strong similarity in potency and composition based on functional assays, with enzymatic activity results showing consistent directionality. These findings were included in the analytical package already submitted to the U.S. Food and Drug Administration (FDA) ahead of a scheduled Biosimilar Biological Product Development (BPD) Type 2a meeting on November 19, 2025, where further discussions on ABP-450's development pathway will take place.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.